Lpath, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2006-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://lpath.com
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers
- Conditions
- Healthy Subjects
- Interventions
- Biological: 0.5 mg/kg LpathomabOther: Saline solution for intravenous infusionBiological: 1.0 mg/kg LpathomabBiological: 3.0 mg/kg LpathomabBiological: 10 mg/kg LpathomabBiological: 20 mg/kg Lpathomab
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2016-05-06
- Lead Sponsor
- Lpath, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02341508
- Locations
- 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States
A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma
- First Posted Date
- 2013-01-07
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Lpath, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01762033
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Florida Cancer Specialists, Inverness, Florida, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
- Conditions
- Exudative Age-related Macular Degeneration
- Interventions
- Drug: 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg EyleaDrug: 4.0 mg iSONEPDrug: 0.5 mg iSONEPDrug: sham injection
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Lpath, Inc.
- Target Recruit Count
- 158
- Registration Number
- NCT01414153
- Locations
- 🇺🇸
Retina Centers, P.C., Tucson, Arizona, United States
🇺🇸Central Plains Eye MDs, Wichita, Kansas, United States
🇺🇸Retina Consultants of Hawaii, Aiea, Hawaii, United States
iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)
- Conditions
- Pigment Epithelial Detachment
- Interventions
- Drug: iSONEP (sonepcizumab/LT1009)
- First Posted Date
- 2011-04-13
- Last Posted Date
- 2013-04-23
- Lead Sponsor
- Lpath, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01334255
- Locations
- 🇺🇸
Palmetto Retina Center, West Columbia, South Carolina, United States
🇺🇸Associates in Ophthalmology, West Mifflin, Pennsylvania, United States
🇺🇸Retina Research Institute of Texas, Abilene, Texas, United States
Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration
- Conditions
- Neovascular Age Related Macular Degeneration
- Interventions
- Biological: iSONEP
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- Lpath, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT00767949
- Locations
- 🇺🇸
Midwest Eye Institute, Indianapolis, Indiana, United States
🇺🇸Center for Retina and Macular Disease, Winter Haven, Florida, United States
🇺🇸Retinal Consultants of Arizona, LTD, Phoenix, Arizona, United States
Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors
- Conditions
- Solid Tumors
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2012-01-31
- Lead Sponsor
- Lpath, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT00661414
- Locations
- 🇺🇸
Premiere Oncology, Santa Monica, California, United States
🇺🇸Pacific Oncology, San Diego, California, United States